Trial Profile
A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, 3-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TD-8236 by Inhalation of Single Ascending Doses in Healthy Subjects (Part A) and Multiple Ascending Doses in Subjects With Stable, Mild Asthma (Part B), and Stable, Moderate-to-Severe Asthma (Part C)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Jul 2022
Price :
$35
*
At a glance
- Drugs TD 8236 (Primary) ; Corticosteroids
- Indications Asthma
- Focus Adverse reactions; Biomarker; First in man
- Sponsors Theravance Biopharma
- 05 Nov 2020 Results presented in a Theravance Biopharma media release.
- 31 Aug 2020 Status changed from recruiting to completed.
- 06 May 2020 According to Theravance Biopharma media release, Part C extension portion of the Phase 1 trial assessing additional biomarkers in more severe asthmatics underway with results expected in 2H 2020.